All‐cause mortality · pregnant women with fetal growth restriction
Tadalafil showed no clear difference in all‐cause mortality compared with placebo or no therapy (low certainty).
1 finding from 1 review
Fetal mortality · pregnant women with fetal growth restriction
Tadalafil showed no clear difference in fetal mortality compared with placebo or no therapy (low certainty).
1 finding from 1 review
Neonatal mortality · pregnant women with fetal growth restriction
Tadalafil showed no clear difference in neonatal mortality compared with placebo or no therapy (low certainty).
1 finding from 1 review
All‐cause mortality · pregnant women with fetal growth restriction
1 finding from 1 review
Fetal mortality · pregnant women with fetal growth restriction
1 finding from 1 review
Neonatal mortality · pregnant women with fetal growth restriction
1 finding from 1 review
Intervention not reported
Total studies: 38 Total participants: 12,985 · people with chronic pain Interventions: duloxetine (all doses combined), milnacipran (all doses combined), mirtazapine (all doses…
1 finding from 1 review
no estimate extracted
38 participants
GRADE not reported
Intervention not reported
Mirtazapine RCTs: 1 Participants: 406 · people with chronic pain Interventions: duloxetine (all doses combined), milnacipran (all doses combined), mirtazapine (all doses…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
Duloxetine RCTs: 26 Participants: 7952 · people with chronic pain Interventions: duloxetine (all doses combined), milnacipran (all doses combined), mirtazapine (all doses…
1 finding from 1 review
no estimate extracted
26 participants
Moderate
Intervention not reported
Milnacipran RCTs: 5 Participants: 3109 · people with chronic pain Interventions: duloxetine (all doses combined), milnacipran (all doses combined), mirtazapine (all doses…
1 finding from 1 review
no estimate extracted
5 participants
Moderate
Mortality before hospital discharge · preterm infants
Caffeine showed no clear difference in all‐cause mortality prior to hospital discharge№ of participants:… compared with other methylxanthines (low certainty).
1 finding from 1 review
RR 1.12 [0.68, 1.84]
Studies not reported
Low
f) Hearing impairment (requiring amplification) № of participants: 6(1 RCT) · preterm infants
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Bronchopulmonary dysplasia/chronic lung disease · preterm infants
Caffeine showed no clear difference in bronchopulmonary dysplasia/chronic lung disease: defined as 28 days… compared with other methylxanthines (low certainty).
1 finding from 1 review
RR 1.4 [0.92, 2.11]
Studies not reported
Low
Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines№ of participants: 30(1 RCT) · preterm infants
It is very uncertain whether caffeine changes side effects (tachycardia, agitation, or feed intolerance) leading… compared with other methylxanthines (very low certainty).
1 finding from 1 review
RR 0.17 [0.02, 1.32]
Studies not reported
Very low
Length of hospital stay · preterm infants
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Seizures · preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Moderate‐severe neurodevelopmental impairment at 18 to 26 months ‐ not measured · preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cerebral palsy · preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
b) Gross motor disability defined as ≥ level 2 according to the GMFCS · preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
c) Developmental delay more than two SDs below population mean on a standardized test of development: cognitive delay № of participants: 79(1 RCT) · preterm infants
It is very uncertain whether caffeine changes c) Developmental delay more than two SDs below population mean on a… compared with other methylxanthines (very low certainty).
1 finding from 1 review
RR 0.17 [0.02, 1.37]
Studies not reported
Very low